Evidence map›Paper›PMID 42243153›Full record

ArticleScientific reports2026

Evaluation of the predictive accuracy of nine staging systems in patients with hepatocellular carcinoma: a multicenter, retrospective study in China.

Shibo Wang, Yu Li, Shuang Leng, Chao Li, Hong Zhu, Jing Lv, Dayong Zheng, Haifeng Lin, Jianhong Zhong, Ming Zhao and 8 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Shibo WangDepartment of Phase I Clinical Trial Center, The First Hospital of Jilin University, Changchun, Jilin, China.
Yu LiDepartment of Medical Oncology, Hongqi Hospital, Mudanjiang Medical University, Mudanjiang, Heilongjiang, China.
Shuang LengDepartment of Hematology and Oncology, Meihekou Central Hospital, Meihekou, Jilin, China.
Chao LiDepartment of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Hong ZhuCancer Center, The First Affiliated Hospital of Soochow University, Soochow, Jiangsu, China.
Jing LvDepartment of Medical Oncology, The First Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Dayong ZhengDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Haifeng LinDepartment of Medical Oncology, The Second Affiliated Hospital of Hainan Medical College, Haikou, Hainan, China.
Jianhong ZhongHepatobiliary Surgery Department, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
Ming ZhaoDepartment of Oncology, Cancer Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Jun XueDepartment of Surgery, Wuhan Union Hospital, Wuhan, Hubei, China.
Peng HuangDepartment of Gastroenterology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.
Zhiyu ChenInstitute of Hepatobiliary Surgery, The Southwest Hospital of Army Medical University, Chongqing, China.
Qian ZhuDepartment of Institute of Hepatobiliary Diseases, the Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
Weijia FangCancer Biotherapy Center, First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China.
Xiufeng LiuJinling Hospital, Nanjing University, Nanjing, Jiangsu, China.
Yan YangDepartment of Medical Oncology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Nanya WangDepartment of Phase I Clinical Trial Center, The First Hospital of Jilin University, Changchun, Jilin, China. wangny@jlu.edu.cn.

Funding

Interdisciplinary Project of Jilin University 04034000002Jilin University Excellent Young Teachers Training Program and Bethune Special Project of Jilin Provincial Department of Science and Technology 3D5204167428
6 · The paper itself

Abstract

There are several staging systems for hepatocellular carcinoma (HCC); however, the best prognostic system for Chinese patients has not been established. The aim of this study was to evaluate nine staging systems and identify the best prognostic staging system for Chinese patients with HCC. This retrospective study included 1,495 patients with HCC from 2012 to 2022 in 17 hospitals in China. The predictive ability of nine HCC staging systems was evaluated based on homogeneity, monotonicity of gradients, Akaike's information criterion, and area under the receiver operating characteristic curve. Overall survival at 1, 3 and 5 years was 59.90%, 40.34%, and 34.83%, respectively. Multivariable Cox analysis identified older age, multiple tumor nodules, maximum tumor size > 5 cm, macrovascular invasion, distant metastases, treatment modalities, worse performance status, low protein, high bilirubin, and high alpha-fetoprotein as independent prognostic factors. The Hong Kong Liver Cancer (HKLC) system showed the highest predictive accuracy for Chinese patients in hepatitis B virus-infected populations and in those undergoing non-curative treatment. The Cancer of the Liver Italian Program showed the best predictive ability in patients with hepatitis C virus infection or in the curative treatment subgroup. HKLC may be the most consistent and reliable prognostic model for patients with HCC in the Chinese population.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsNeoplasm StagingAdultAgedChinaFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesROC CurveLiver cancerPrognostic evaluationStaging systemTherapeutic approaches

Identifiers

PMID42243153
PMCPMC13478287

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.